JAC Advance Access originally published online on January 21, 2005
Journal of Antimicrobial Chemotherapy 2005 55(2):162-169; doi:10.1093/jac/dkh528
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
JAC vol.55 no.2 © The British Society for Antimicrobial Chemotherapy 2005; all rights reserved
Characterization of recombinant influenza B viruses with key neuraminidase inhibitor resistance mutations
1 School of Animal and Microbial Sciences, University of Reading, Whiteknights, PO Box 228, Reading RG6 6AJ; 2 Medicine Research Centre, GlaxoSmithKline, Stevenage SG1 2NY, UK
* Corresponding author. Fax: +44-118-9316671; Email: w.s.barclay{at}reading.ac.uk
Objectives and methods: An influenza B virus plasmid-based rescue system was used to introduce site-specific mutations, previously observed in neuraminidase (NA) inhibitor-resistant viruses, into the NA protein of six recombinant viruses. Three mutations observed only among in vitro selected zanamivir-resistant influenza A mutants were introduced into the B/Beijing/1/87 virus NA protein, to change residue E116 to glycine, alanine or aspartic acid. Residue E116 was also mutated to valine, a mutation found in the clinic among oseltamivir-resistant viruses. An arginine to lysine change at position 291 (292 N2 numbering) mimicked that seen frequently in influenza A N2 clinical isolates resistant to oseltamivir. Similarly, an arginine to lysine change at position 149 (152 in N2 numbering) was made to reproduce the change found in the only reported zanamivir-resistant clinical isolate of influenza B virus. In vitro selection and prolonged treatment in the clinic leads to resistance pathways that require compensatory mutations in the haemagglutinin gene, but these appear not to be important for mutants isolated from immunocompetent patients. The reverse genetics system was therefore used to generate mutants containing only the NA mutation.
Results and conclusions: With the exception of a virus containing the E116G mutation, mutant viruses were attenuated to different levels in comparison with wild-type virus. This attenuation was a result of altered NA activity or stability depending on the introduced mutation. Mutant viruses displayed increased resistance to zanamivir, oseltamivir and peramivir, with certain viruses displaying cross-resistance to all three drugs.
Keywords: reverse genetics , antivirals , zanamivir , oseltamivir , peramivir
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  H.-L. Yen, N. A. Ilyushina, R. Salomon, E. Hoffmann, R. G. Webster, and E. A. Govorkova Neuraminidase Inhibitor-Resistant Recombinant A/Vietnam/1203/04 (H5N1) Influenza Viruses Retain Their Replication Efficiency and Pathogenicity In Vitro and In Vivo J. Virol., November 15, 2007; 81(22): 12418 - 12426. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Zurcher, P. J. Yates, J. Daly, A. Sahasrabudhe, M. Walters, L. Dash, M. Tisdale, and J. L. McKimm-Breschkin Mutations conferring zanamivir resistance in human influenza virus N2 neuraminidases compromise virus fitness and are not stably maintained in vitro J. Antimicrob. Chemother., October 1, 2006; 58(4): 723 - 732. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-L. Yen, E. Hoffmann, G. Taylor, C. Scholtissek, A. S. Monto, R. G. Webster, and E. A. Govorkova Importance of neuraminidase active-site residues to the neuraminidase inhibitor resistance of influenza viruses. J. Virol., September 1, 2006; 80(17): 8787 - 8795. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. P. Mishin, F. G. Hayden, and L. V. Gubareva Susceptibilities of Antiviral-Resistant Influenza Viruses to Novel Neuraminidase Inhibitors Antimicrob. Agents Chemother., November 1, 2005; 49(11): 4515 - 4520. [Abstract] [Full Text] [PDF]
|
|